MARKET

LJPC

LJPC

La Jolla Pharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.02
-0.03
-0.50%
After Hours: 6.02 0 0.00% 16:27 11/15 EST
OPEN
6.14
PREV CLOSE
6.05
HIGH
6.45
LOW
5.94
VOLUME
309.25K
TURNOVER
--
52 WEEK HIGH
16.44
52 WEEK LOW
5.01
MARKET CAP
163.43M
P/E (TTM)
-1.0132
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of LJPC and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

LJPC News

  • La Jolla Pharmaceutical Company Just Reported And Analysts Have Been Cutting Their Estimates
  • Simply Wall St..1d ago
  • La Jolla Pharmaceutical EPS misses by $0.02, misses on revenue
  • seekingalpha.4d ago
  • La Jolla Pharmaceutical (LJPC) Reports Q3 Loss, Misses Revenue Estimates
  • Zacks.4d ago
  • La Jolla Pharmaceutical Q3 EPS $(1.08) Up From $(1.93) YoY, Sales $5.706M Up From $3.47M YoY
  • Benzinga.4d ago

More

Industry

Biotechnology & Medical Research
+1.25%
Pharmaceuticals & Medical Research
+1.34%

Hot Stocks

Name
Price
%Change

About LJPC

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH). It has initiated a Phase III trial of LJPC-501 for the treatment of CRH, called the Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS) Phase III trial. LJPC-401 is its formulation of synthetic human hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is its next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections, as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.
More

Webull offers La Jolla Pharmaceutical Company (LJPC) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.